<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02234687</url>
  </required_header>
  <id_info>
    <org_study_id>13-00609</org_study_id>
    <nct_id>NCT02234687</nct_id>
  </id_info>
  <brief_title>A mGlu2/3 Agonist in the Treatment of PTSD</brief_title>
  <official_title>A mGlu2/3 Agonist in the Treatment of PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we propose to employ a randomized, double-blind, placebo-controlled,
      outpatient clinical trial to test the efficacy, safety, and tolerability of a 160 mg and 40
      mg challenge of the mGlu2/3 agonist pomaglumetad methionil relative to placebo in modulating
      fear-potentiated startle response and behavior in adults with post-traumatic stress disorder
      (PTSD) (N=30). Each participant will receive a single dose of the study drug (40 mg vs 160 mg
      vs placebo in a 1:1:1 ratio).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The original PI, Alexander Neumeister, left NYULMC. No data was analyzed.
  </why_stopped>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">September 11, 2016</completion_date>
  <primary_completion_date type="Actual">February 11, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate the Effect of 160mg and 40mg of Pomaglumetad Methionil</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the effect of 160mg and 40mg challenge of the mGlu2/3 receptor agonist pomaglumetad methionil relative to placebo in mitigating fear-potentiated startle using the neutral-predictable-unpredictable fear-potentiated startle paradigm in adults with post-traumatic stress disorder (PTSD). The primary index of unpredictable fear will be the difference score between startle magnitude in safe and unpredictable conditions in the absence of the cue.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, one dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomaglumetad Methionil 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomaglumetad Methionil 40mg, one dose, one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomaglumetad Methionil 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomaglumetad Methionil 160mg, one dose, one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomaglumetad Methionil 160mg</intervention_name>
    <description>Pomaglumetad Methionil 160mg, one dose, one time</description>
    <arm_group_label>Pomaglumetad Methionil 160mg</arm_group_label>
    <other_name>LY2140023</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomaglumetad Methionil 40mg</intervention_name>
    <description>Pomaglumetad Methionil 40mg, one dose, one time</description>
    <arm_group_label>Pomaglumetad Methionil 40mg</arm_group_label>
    <other_name>LY2140023</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, one dose, one time</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between 18 and 60 years of age, any race

          -  Primary, current Axis I diagnosis of post traumatic stress disorder (PTSD) according
             to Diagnostic and Statistical Manual of Mental Disorders - IV (DSM-IV) criteria

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Past or current presence of psychotic symptoms, or diagnosis of a lifetime psychotic
             disorder including schizophrenia, schizoaffective disorder, bipolar disorder

          -  History of moderate or severe traumatic brain injury (TBI) with loss of consciousness

          -  Lifetime history of seizure disorder

          -  Current diagnosis of obsessive-compulsive disorder (OCD)

          -  Current diagnosis of bulimia nervosa or anorexia nervosa; or substance use disorder

          -  Alcohol or drug abuse in the past 90 days, or dependence in the past year.

          -  Individuals with a cumulative lifetime history of intravenous substance abuse longer
             than 1 year.

          -  Severe dissociation, defined as a Clinician Administered Dissociative States Scale
             (CADSS) score greater than 60 at baseline

          -  Patients with creatinine clearance &lt;60 milliliters (mL)/min (moderate renal
             impairment)

          -  Current pregnancy or breast feeding; medical conditions that could interfere with
             correct interpretation of study data, i.e., individuals with the following medical
             conditions will be excluded: cancer in the past year, stroke, heart attack, angina,
             neurological disease (multiple sclerosis, epilepsy, Parkinson's disease), central
             nervous system (CNS) lesions including TBI with loss of consciousness, dementing
             illness, and/or liver or kidney disease. Patients with QT interval &gt;450 msec (males)
             and &gt;470 msec (females).

          -  Participants who have started new medication regimen for PTSD within 3 months prior to
             study start and subjects taking fluoxetine

          -  Current suicidality defined by emergent Columbia Suicide Severity Rating Scale
             (CSSRS)-defined suicidal behavior, a suicidal ideation score of 5 (indicating active
             suicidal ideation with specific plan and some level of intent) or 4 (indicating active
             suicidal ideation with some intent to act, without specific plan) on the CSSRS or in
             the absence of a CSSRS suicidal ideation score of 5 or 4 or CSSRS-defined suicidal
             behavior, if the investigator determines the patient to have a significant short-term
             risk for a suicide attempt.

          -  Individuals with active suicidal risk, active self-mutilation or aggressive behavior
             with threatening behavior toward others within the past year, as judged by the
             Principal Investigator

          -  Pregnant or lactating women

          -  Legal and Financial: Current legal proceedings resulting from the traumatic events.
             People whose continued receipt of financial benefits is contingent upon maintaining
             PTSD symptoms or who are waiting for a decision concerning the receipt of financial
             benefits based upon PTSD symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Marmar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>September 3, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2014</study_first_posted>
  <results_first_submitted>May 4, 2016</results_first_submitted>
  <results_first_submitted_qc>March 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2018</results_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post-traumatic stress disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>No Outcome Measures Analyzed; Study Terminated</recruitment_details>
      <pre_assignment_details>No Outcome Measures Analyzed; Study Terminated</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>40 mg Poma</title>
          <description>Study Terminated. No outcome measures were analyzed</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Study Terminated. No outcome measures were analyzed</description>
        </group>
        <group group_id="P3">
          <title>160 mg Poma</title>
          <description>Study Terminated. No outcome measures were analyzed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6">Study Terminated. No outcome measures were analyzed</participants>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Study Terminated. No outcome measures were analyzed</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>40 mg Poma</title>
        </group>
        <group group_id="B3">
          <title>160 mg Poma</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate the Effect of 160mg and 40mg of Pomaglumetad Methionil</title>
        <description>To evaluate the effect of 160mg and 40mg challenge of the mGlu2/3 receptor agonist pomaglumetad methionil relative to placebo in mitigating fear-potentiated startle using the neutral-predictable-unpredictable fear-potentiated startle paradigm in adults with post-traumatic stress disorder (PTSD). The primary index of unpredictable fear will be the difference score between startle magnitude in safe and unpredictable conditions in the absence of the cue.</description>
        <time_frame>6 months</time_frame>
        <population>10 patients were enrolled and data for these 10 patients was not analyzed. Assuming a 2-tailed test,power=0.80, alpha=0.05, a total sample size of 30 (10 per group) is required to detect a moderate differential effect size change of a 160mg or 40 mg dose of pomaglumated methionil relative to placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo, one dose, one time</description>
          </group>
          <group group_id="O2">
            <title>Pomaglumetad Methionil 160mg</title>
            <description>Pomaglumetad Methionil 160mg, one dose, one time Pomaglumetad Methionil 160mg: Pomaglumetad Methionil 160mg, one dose, one time</description>
          </group>
          <group group_id="O3">
            <title>Pomaglumetad Methionil 40mg</title>
            <description>Pomaglumetad Methionil 40mg, one dose, one time Pomaglumetad Methionil 40mg: Pomaglumetad Methionil 40mg, one dose, one time</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Effect of 160mg and 40mg of Pomaglumetad Methionil</title>
          <description>To evaluate the effect of 160mg and 40mg challenge of the mGlu2/3 receptor agonist pomaglumetad methionil relative to placebo in mitigating fear-potentiated startle using the neutral-predictable-unpredictable fear-potentiated startle paradigm in adults with post-traumatic stress disorder (PTSD). The primary index of unpredictable fear will be the difference score between startle magnitude in safe and unpredictable conditions in the absence of the cue.</description>
          <population>10 patients were enrolled and data for these 10 patients was not analyzed. Assuming a 2-tailed test,power=0.80, alpha=0.05, a total sample size of 30 (10 per group) is required to detect a moderate differential effect size change of a 160mg or 40 mg dose of pomaglumated methionil relative to placebo.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo, one dose Placebo: Placebo, one dose, one time</description>
        </group>
        <group group_id="E2">
          <title>Pomaglumetad Methionil 160mg</title>
          <description>Pomaglumetad Methionil 160mg, one dose, one time</description>
        </group>
        <group group_id="E3">
          <title>Pomaglumetad Methionil 40mg</title>
          <description>Pomaglumetad Methionil 40mg, one dose, one time</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting after receiving medication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PTSD symptoms became worse after the study</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>10 patients were enrolled and data for these 10 patients was not analyzed because enrollment must reach a certain threshold for reporting.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Charles Marmar, MD</name_or_title>
      <organization>New York University School of Medicine</organization>
      <phone>646 754 4855</phone>
      <email>Charles.Marmar@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

